How this instrument works
SCORAD has three parts. Extent (A) is the percentage of body surface affected, 0 to 100, assessed with the rule of nines. Intensity (B) sums six signs rated 0 to 3 each — erythema, edema or papulation, oozing or crusting, excoriation, lichenification, and dryness of unaffected skin — for a possible range of 0 to 18. Subjective symptoms (C) add the patient's own rating of itch and sleep loss over the past three days, each 0 to 10, for a possible range of 0 to 20. The three combine as SCORAD = A/5 + 7B/2 + C.
That formula weights the three parts very unevenly on purpose. Each point of B, the intensity sum, is worth 3.5 points toward the total, thanks to the 7-over-2 multiplier — nearly seventeen times what a single point of A is worth, since extent is divided by 5. The European Task Force on Atopic Dermatitis chose this weighting because their consensus panel found the visible intensity signs tracked most closely with how severe the disease actually was, more than raw surface area or the two patient-reported symptoms, which are added at a plain one-to-one rate.
A SCORAD result is commonly grouped into mild (under 25), moderate (25 to 50), and severe (above 50) disease. This isn't part of the original 1993 formula itself but a widely used interpretive convention discussed in later literature on applying the index in practice, including a 2007 review of scoring interpretation published in the British Journal of Dermatology. The index still leans on a clinician's visual judgment for five of its nine components, so two examiners can land on somewhat different numbers for the same skin — it's built for tracking one patient's own trend over time, not for laboratory-grade precision between two separate assessments.
- Estimate extent (A) — the percentage of body surface affected, 0 to 100, using the rule of nines.
- Rate each of the six intensity signs — erythema, edema/papulation, oozing/crusting, excoriation, lichenification, dryness — from 0 (none) to 3 (severe).
- Enter pruritus and sleep loss over the past three days, each on a 0-10 scale, usually from the patient's own rating.
- Read B (intensity sum), C (subjective sum), and the combined SCORAD total.
Worked example — 20% extent, moderate intensity and symptoms
Extent affects 20% of body surface: A/5 = 20/5 = 4. Six intensity signs — erythema 2, edema 1, oozing 0, excoriation 2, lichenification 1, dryness 2 — sum to B = 8. The intensity term: 7 × 8 / 2 = 28.
Pruritus rated 5 out of 10, sleep loss rated 3 out of 10, so C = 5 + 3 = 8. Total SCORAD: 4 + 28 + 8 = 40 — inside the commonly used moderate band of 25 to 50.
Questions
Why is the intensity score (B) weighted so much more heavily than extent (A)?
Because the 7-over-2 multiplier makes each point of B worth 3.5 points of the final total, versus a fifth of a point for each percentage point of A. The European Task Force on Atopic Dermatitis chose that imbalance deliberately: when they built the index in 1993, the visible intensity signs — redness, oozing, thickened skin, and the rest — tracked more closely with how severe clinicians judged a case to be than raw body-surface extent did, so intensity was given the dominant vote.
What counts as mild, moderate, or severe on the SCORAD scale?
A widely used convention, discussed in secondary literature on interpreting the index such as a 2007 British Journal of Dermatology review, groups scores under 25 as mild, 25 to 50 as moderate, and above 50 as severe. These bands appear often in trial reporting and clinical practice, though the maximum possible score is 103, so severe disease still spans a wide range.
Why are pruritus and sleep loss weighted 1-to-1 while intensity is weighted 3.5-to-1?
Pruritus and sleep loss come straight from the patient rather than an examiner, and the 1993 consensus panel treated that subjective report as valuable but less reliably comparable across different people's pain thresholds and sleep habits than a clinician's direct visual rating of the skin. Weighting C at a flat 1-to-1 rate keeps its influence real without letting it dominate a score built mainly around what's visibly happening on the skin.
Is SCORAD the same as EASI?
No — related but different tools. EASI scores four visible signs across four body regions with no patient-reported component at all, while SCORAD folds extent, six intensity signs, and the patient's own itch and sleep-loss ratings into one number. A clinic that wants the subjective symptom burden captured directly generally reaches for SCORAD; one focused purely on visible signs may prefer EASI.
How reliable is a SCORAD score between two different examiners?
Reasonably consistent for a clinical tool, but not exact — five of the nine components rest on visual judgment calls about redness, thickness, or crusting that can shift a few points between two trained examiners looking at the same skin. It's best used to track one patient's own trend over repeated visits rather than to compare small differences between two separate assessments.
Does a SCORAD score diagnose atopic dermatitis?
No. It assumes atopic dermatitis has already been diagnosed by a clinician using recognized criteria, then measures how extensive and severe that existing diagnosis currently is. It isn't designed to distinguish eczema from other skin conditions that can look similar on the surface.
References
- European Task Force on Atopic Dermatitis, 1993, Dermatology — SCORAD consensus report (DOI)
- Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB, 2007, Br J Dermatol — scoring interpretation (PubMed)
Read this first: This instrument computes a screening figure from population formulas — it is not a diagnosis, and it cannot see the whole picture a clinician can. Use it to inform a conversation, not to replace one.